Science
FDA Removes REMS Requirement for Autologous CAR T Cell Immunotherapies Enhancing Patient Access
This decision follows a thorough safety reassessment that concluded the REMS are no longer necessary to ensure that the benefits of these gene therapies outweigh their risks.
Subscriber access
Full story for subscribers
Sign in with your subscribed Google account to read the full article.
Checking your access…